pDJA1, a cardiac specific gene, corresponding proteins, and uses thereof

Abstract

The present invention provides novel nucleic acid and protein sequences for methods and compositions for treating, screening, and diagnosing cardiovascular disease and methods for using these genes and gene products for prevention of cardiac cell death and prevention of cardiac tissue damage resulting from ischemic events in cardiac tissue, as well as other tissue that is subject to damage resulting from an ischemic event. The genes, gene products and agents of the invention are also useful for treating other related clinical or coronary events such as angina, myocardial infarct (MI), and stroke, for monitoring the effectiveness of their treatment, and for drug development. The genes, gene products and agents of the present invention are also provided as pharmaceutical compositions for treatment of cardiovascular disease, ischemic heart disease, myocardial infarct and related conditions. Kits are also provided for the diagnosis, treatment and prognosis of cardiac diseases and related conditions.

1 . An isolated nucleic acid, comprising a pDJA1 coding sequence. 
     
     
         2 . The nucleic acid of  claim 1 , wherein the nucleic acid comprises the sequence of SEQ ID NO: 1, and recombinant DNA molecules, cloned genes, degenerate variants, mutants, analogs, or fragments thereof. 
     
     
         3 - 4 . (canceled) 
     
     
         5 . A biomarker associated with and/or predictive of cardiovascular disease, wherein said cardiovascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, ischemic heart disease, myocardial infarction, angina, stroke and other related conditions related to or resulting from an ischemic event, comprising the nucleic acid of SEQ ID NO:1. 
     
     
         6 - 17 . (canceled) 
     
     
         18 . A pharmaceutical composition comprising a therapeutically effective amount of pDJA1 nucleic acid and a pharmaceutically acceptable carrier. 
     
     
         19 . (canceled) 
     
     
         20 . A pharmaceutical composition comprising a therapeutically effective amount of an agent that upregulates the expression and/or activity of the isolated nucleic acid of  claim 1  and a pharmaceutically acceptable carrier.